Previous 10 | Next 10 |
THE WOODLANDS, Texas, June 13, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for Zynquista TM (sotagliflozin) at the virtual 80 th American Diabetes Association (ADA) Scientific Sessions including additional efficacy and safet...
Would You Add These To Your List Of Penny Stocks To Buy? Penny stocks have been flying high this week and May has seen some big moves. You’ve got to admit the federal reserve and government have helped propel things a bit further in Q2. On Wednesday, Federal Reserve Chair Jerome Powel...
THE WOODLANDS, Texas, May 13, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s ® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines t...
The frustrating reality for a lot of biotech shareholders is that while these stocks can enjoy strong runs on thesis-altering data announcements, a lot of time as a biotech investor is spent waiting. Such is the case for Lexicon Pharmaceuticals ( LXRX ) today. Whatever commercial sales poten...
Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) have soared today, closing out the session with gains of 12%, after the company reported first-quarter earnings results. The biotech beat expectations for both the top and bottom lines. Revenue in the first quarter declined 13% to $...
Image source: The Motley Fool. Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Q1 2020 Earnings Call Apr 27, 2020 , 8:00 a.m. ET Operator Continue reading
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2020 Earnings Conference Call April 27, 2020 08:00 AM ET Company Participants Dr. Kimberly Lee - Head, IR and Corporate Strategy Lonnel Coats - President and CEO Alex Santini - EVP and Chief Commercial Officer Dr. Pablo Lapuerta - EVP and...
Lexicon Pharmaceuticals ( LXRX ) Q1 results : More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q1 GAAP EPS of -$0.63 beats by $0.05 . More news on: Lexicon Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
THE WOODLANDS, Texas, April 27, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended March 31, 2020. “We achieved 17% growth in XERMELO net sales for the first quarter o...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...